514 related articles for article (PubMed ID: 19863841)
1. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease.
Schmand B; Huizenga HM; van Gool WA
Psychol Med; 2010 Jan; 40(1):135-45. PubMed ID: 19863841
[TBL] [Abstract][Full Text] [Related]
2. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
3. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study.
Sluimer JD; Bouwman FH; Vrenken H; Blankenstein MA; Barkhof F; van der Flier WM; Scheltens P
Neurobiol Aging; 2010 May; 31(5):758-64. PubMed ID: 18692273
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Rusinek H; Li J; Tsui W; Saint Louis LA; Clark CM; Tarshish C; Li Y; Lair L; Javier E; Rich K; Lesbre P; Mosconi L; Reisberg B; Sadowski M; DeBernadis JF; Kerkman DJ; Hampel H; Wahlund LO; Davies P
Neurobiol Aging; 2006 Mar; 27(3):394-401. PubMed ID: 16125823
[TBL] [Abstract][Full Text] [Related]
5. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P
Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336
[TBL] [Abstract][Full Text] [Related]
6. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.
Bouwman FH; Schoonenboom SN; van der Flier WM; van Elk EJ; Kok A; Barkhof F; Blankenstein MA; Scheltens P
Neurobiol Aging; 2007 Jul; 28(7):1070-4. PubMed ID: 16782233
[TBL] [Abstract][Full Text] [Related]
7. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
Parnetti L; Lanari A; Silvestrelli G; Saggese E; Reboldi P
Mech Ageing Dev; 2006 Feb; 127(2):129-32. PubMed ID: 16274728
[TBL] [Abstract][Full Text] [Related]
8. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
9. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
[TBL] [Abstract][Full Text] [Related]
10. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
[TBL] [Abstract][Full Text] [Related]
11. CSF biomarkers for mild cognitive impairment.
Blennow K
J Intern Med; 2004 Sep; 256(3):224-34. PubMed ID: 15324365
[TBL] [Abstract][Full Text] [Related]
12. Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI.
Nordlund A; Rolstad S; Klang O; Lind K; Pedersen M; Blennow K; Edman A; Hansen S; Wallin A
J Int Neuropsychol Soc; 2008 Jul; 14(4):582-90. PubMed ID: 18577287
[TBL] [Abstract][Full Text] [Related]
13. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
[TBL] [Abstract][Full Text] [Related]
14. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
16. [Diagnosing the mild cognitive impairment stage of Alzheimer's disease].
Maruyama M; Matsui T; Tanji H; Ootsuki M; Nemoto M; Tomita N; Okamura N; Matsushita S; Higuchi S; Kodama M; Arai H; Sasaki H
Seishin Shinkeigaku Zasshi; 2004; 106(3):269-80. PubMed ID: 15164576
[TBL] [Abstract][Full Text] [Related]
17. Subcortical vascular dementia biomarker pattern in mild cognitive impairment.
Bjerke M; Andreasson U; Rolstad S; Nordlund A; Lind K; Zetterberg H; Edman A; Blennow K; Wallin A
Dement Geriatr Cogn Disord; 2009; 28(4):348-56. PubMed ID: 19864909
[TBL] [Abstract][Full Text] [Related]
18. [MCI-plus: mild cognitive impairment with rapid progression. Part II: Biomarkers and research methods].
Förstl H; Werheid K; Ulm K; Schönknecht P; Schmidt R; Pantel J; Hörr R; Gutzmann H; Gertz HJ; Frölich L; Bickel H
Dtsch Med Wochenschr; 2009 Jan; 134(3):88-91. PubMed ID: 19142839
[TBL] [Abstract][Full Text] [Related]
19. [Alzheimer's disease as brain amyloidosis: diagnosis using cerebrospinal fluid abeta and tau].
Shoji M
Rinsho Byori; 2006 May; 54(5):503-8. PubMed ID: 16789421
[TBL] [Abstract][Full Text] [Related]
20. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.
Andreasen N; Blennow K
Clin Neurol Neurosurg; 2005 Apr; 107(3):165-73. PubMed ID: 15823670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
